Health Plan AI Adoption: Why EU Payers Trail the US — and Where the White Space Sits for HealthTech Vendors
The analysis of AI deployment across the top 20 health insurers in the US and Europe reveals a clear pattern: payer investment in AI has moved well beyond the experimental stage, but implementation remains highly uneven. US private insurers have raced ahead with consumer-facing generative assistants and prior-authorization automation, while European statutory and national payers Learn more...
Best-in-Class Beyond the Pill Solutions: How Pharma Should Evaluate and Select BtP Vendor Partners
The term “beyond-the-pill” has become widely used across the pharmaceutical industry, yet its definition remains inconsistent and often misrepresented. Vendors position a broad range of digital solutions under this label, making direct comparisons difficult and complicating vendor selection for pharma companies. The absence of a standardized classification framework further limits transparency around capabilities and differentiation. Learn more...
Why an IP Strategy Matters Before Fundraising or Exit
Many startups treat intellectual property as a legal task that can be addressed later. In practice, it plays a central role in how investors, partners, and acquirers assess the long-term value of a company. Evidence from multiple studies shows that startups with a defined IP strategy raise more capital, secure more partnerships, and achieve higher Learn more...
Drug Companion Apps in Pharma: How to Choose the Right Vendor and Maximize ROI
Digital drug companion apps are rapidly becoming standard for high-value therapies, with over 3,000 new drug–app combinations expected in the next four years. Selecting the right vendor has evolved into a cross-functional investment decision, requiring alignment across brand, medical, IT, compliance, and market access teams. The R2GConnect framework provides a structured approach to benchmark pricing Learn more...
Why Only 1 in 5 HealthTech Startups Succeeds in Raising External Capital
Only 19% of healthtech startups successfully raise external capital, often failing due to poor preparation rather than a lack of funds. To bridge this gap, R2GConnect’s free “Get Investor-Ready” track offers expert-led sessions on regulatory strategy, market intelligence, and pitch refinement to help founders secure funding. Over the past few years, and following the post-COVID Learn more...
The Data Utility Gap – Why Hospitals Must Pivot from Collection to Intelligence
Hospitals face a dangerous paradox: massive data volume but limited operational insight. To combat burnout and financial penalties, executives are urgently seeking AI solutions for clinical decision support, patient forecasting, and data integration. R2GConnect’s Open Call connects vendors directly with hospitals looking to deploy these mission-critical tools in 2026. The 2026 Strategic Landscape The global Learn more...
Beyond Care Delivery: How Hospitals Are Entering the €1B HealthTech Services Market
Hospitals are in financial trouble. At the same time, digital health startups are desperate for specialised external support. The cross-point between those two trends is a new €1B+ market where hospitals become service providers. Hospitals are beginning to sell services to digital health companies. Not clinical care, but validation, testing, data services, acceleration programs, regulatory Learn more...
AI-Enabled Hospital Workflow Automation & Efficiency Tools: The New Operating System for Modern Health Systems
AI is rapidly becoming the operational backbone of hospitals. It’s optimizing ORs, beds, staffing, supply chains, and administrative workflows. These systems cut waste, reduce bottlenecks, and remove repetitive tasks that drain clinical time. Hospitals deploying AI-driven automation are gaining measurable improvements in throughput, cost efficiency, and overall operational stability — essentially building a smarter operating Learn more...
AI-Powered Companion Apps: Pharma’s Next Competitive Battleground
Medication companion apps used to sit on the fringes of digital health. Today, they are moving straight into the center of pharma’s commercial and clinical strategies. What started as simple reminder tools has turned into a fast-expanding digital layer that influences prescribing, adherence, real-world evidence generation, and long-term therapy outcomes. The shift is not subtle. Learn more...